Science Note
[Jul. 9, 2024] Previous Science Note
Diseases Associated with Ferroptosis: Cancer, Neurodegeneration, and Age-Related Diseases
Ferroptosis and senescence are two distinct cellular processes that significantly impact disease initiation and progression. Ferroptosis is an iron-dependent form of cell death characterized by lipid peroxidation that plays a critical role in neurodegenerative diseases by promoting neuronal death and in cancer where it can either inhibit or promote tumor growth depending on the context. Senescence involves a state of permanent cell cycle arrest that acts as a tumor suppressor by preventing the proliferation of damaged cells, but also contributes to aging and tissue dysfunction. Both processes are integral to the pathophysiology of several diseases and provide potential targets for therapeutic intervention. |
||
Aging promotes metabolic dysfunction-associated steatotic liver disease by inducing ferroptotic stress |
Microglial ferroptotic stress causes non-cell autonomous neuronal death |
Fatty acid binding protein 5 suppression attenuates obesity-induced hepatocellular carcinoma by promoting ferroptosis and intratumoral immune rewiring |
Point of Interest - Aged mice show increased hepatocyte ferroptosis and liver degeneration under conditions that induce metabolic stress. - Inhibition of ferroptosis in aged mice reverses age-related liver damage. |
Point of Interest - Human amyotrophic lateral sclerosis (ALS) spinal cord tissue shows ferroptosis signatures, that are also observed in the ALS mouse model, where ferroptosis inhibition is neuroprotective. - Ferroptosis in microglia can cause non-cell autonomous neuronal death, suggesting a novel pathophysiological role in neurodegenerative diseases. |
Point of Interest - FABP5 inhibition reduces HCC burden in mice by promoting a pro-inflammatory tumor microenvironment. - FABP5 inhibition activates CD8+ T cells and increases expression of CD80 and CD86, T cell activation molecules in tumor-associated macrophages. |
Related Techniques | ||
Ferrous ion (Fe2+) detection | FerroOrange(intracellular), Mito-FerroGreen(mitochondrial) | |
Lipid peroxidation detection | Liperfluo(intracellular), MitoPeDPP(mitochondrial) | |
Cellular senescence detection | SPiDER-βGal for live-cell imaging or flow cytometry / microplate reader / tissue samples | |
Mitophagy or autophagy detection | Mitophagy Detection Kit, Autophagic Flux Assay Kit | |
Total ROS detection | Highly sensitive DCFH-DA or Photo-oxidation Resistant DCFH-DA | |
Mitochondrial superoxide detection | MitoBright ROS Deep Red - Mitochondrial Superoxide Detection | |
Mitochondrial membrane potential detection | JC-1 MitoMP Detection Kit, MT-1 MitoMP Detection Kit | |
Lysosomal function | Lysosomal Acidic pH Detection Kit -Green/Red and Green/Deep Red | |
Glutathione Quantification | GSSG/GSH Quantification Kit | |
Glycolysis/Oxidative phosphorylation Assay | Glycolysis/OXPHOS Assay Kit | |
![]() |
||
Related Applications | ||
Induction of Ferroptosis by ErastinErastin is a known inducer of ferroptosis. By inhibiting the cystine transporter (xCT), erastin inhibits the uptake of cystine. Cystine is the raw material for GSH. Therefore, Erastin ultimately decreases the amount of GSH. Decreased GSH then results in lipid peroxide accumulation and induction of ferroptosis. Using erastin-treated A549 cells, we measured intracellular Fe2+, ROS, lipid peroxide, glutathione, glutamate release into the extracellular space, and cystine uptake. As a result, inhibition of xCT by elastin was observed and also the release of glutamate and uptake of cystine were decreased. Furthermore, elastin treatment decreased intracellular glutathione while it increased intracellular Fe2+ , ROS, and lipid peroxides.
|